Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex
pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains …

The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling
pathway was discovered more than a quarter-century ago. As a fulcrum of many vital cellular …

Atopic dermatitis (AD) is a common yet complex skin disease, posing a therapeutic
challenge with increasingly recognized different phenotypes among variable patient …

Importance Abrocitinib, an oral, once-daily Janus kinase 1 selective inhibitor, was effective
and well tolerated in a phase 3 monotherapy trial of patients with moderate-to-severe atopic …

Atopic dermatitis (AD) is a common inflammatory skin disorder characterized by recurrent
eczematous lesions and intense itch. Although it most often starts in infancy and affects …

Interleukin-17 (IL-17) is an essential proinflammatory cytokine, which is mainly secreted by
the CD4+ helper T cells (Th17 cells) and subsets of innate lymphoid cells. IL-17A is …

abstract Atopic dermatitis (AD) is a heterogenous disorder and can be classified into
different types. Stratification of subtypes may enable personalized medicine approaches. AD …

Background Dupilumab is an IL-4 receptor α mAb inhibiting signaling of IL-4 and IL-13, key
drivers of type 2–driven inflammation, as demonstrated by its efficacy in patients with …

Background Atopic dermatitis is a chronic inflammatory skin disease characterized by
pruritic skin lesions. Objective We sought to evaluate the safety and efficacy of multiple …

Background Atopic dermatitis (AD) is a prevalent inflammatory skin disease with a complex
pathogenesis involving immune cell and epidermal abnormalities. Despite whole tissue …